Wells Fargo
OBIO icon

Wells Fargo’s Orchestra BioMed OBIO Stock Holding History

Wells Fargo’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
+36,356
New +$149K ﹤0.01% 5339
2025
Q3 		– Sell
-4,474
Closed -$12K – 7297
2025
Q2 		$12K Sell
4,474
-8,979
-67% -$26.2K ﹤0.01% 5906
2025
Q1 		$57.6K Buy
13,453
+297
+2% +$1.48K ﹤0.01% 5353
2024
Q4 		$52.6K Buy
13,156
+3,992
+44% +$21.4K ﹤0.01% 5466
2024
Q3 		$47.1K Buy
9,164
+140
+2% +$915 ﹤0.01% 5364
2024
Q2 		$73.5K Buy
9,024
+4,576
+103% +$26.5K ﹤0.01% 5116
2024
Q1 		$23.4K Buy
4,448
+585
+15% +$3.96K ﹤0.01% 5537
2023
Q4 		$35.3K Buy
3,863
+863
+29% +$5.89K ﹤0.01% 5401
2023
Q3 		$26.2K Buy
3,000
+1,177
+65% +$7.91K ﹤0.01% 5489
2023
Q2 		$12.8K Buy
1,823
+1,733
+1,926% +$26.3K ﹤0.01% 5846
2023
Q1 		$1.76K Buy
+90
New +$1.04K ﹤0.01% 6252

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Wells Fargo's OBIO Position: Q2 2026 in Review

Wells Fargo opened a new position in Orchestra BioMed (OBIO) in Q2 2026: 36,356 shares worth $157K. The stake represents ﹤0.01% of the portfolio and ranks #5339 among its holdings. This is a return to the name: Wells Fargo previously reported a position in OBIO as recently as Q2 2025.

Wells Fargo first reported a position in OBIO in Q1 2023 and has held it in 11 quarters since. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Wells Fargo held 36,356 shares of Orchestra BioMed worth $157K as of Q2 2026.
  • Orchestra BioMed was a new Wells Fargo position in Q2 2026.
  • Orchestra BioMed made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5339 holding.
  • Wells Fargo first reported a position in Orchestra BioMed in Q1 2023 and has held it in 11 quarters since.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.